A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-12-06
Adverse events
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 77); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-18 (study day 145); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-09 (study day 197); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 242); relationship: N
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-06 (study day 409); relationship: Y
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-04-13 (study day 476); relationship: not assessed
Data queries
No data queries.